MarketScreener Homepage > Equities > Swiss Exchange > Roche Holding AG ROG CH0012032048

Report

Delayed Swiss Exchange - 09/18 11:30:53 am
343.1	CHF		+1.84%

09/19

ROCHE : presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

09/19

ROCHE : presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020

09/19

GENENTECH : Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Summary

Quotes 5-day view Delayed Quote.

Delayed Swiss Exchange

09/14/2020	09/15/2020	09/16/2020	09/17/2020	09/18/2020	Date
330(c)	335.45(c)	337.15(c)	336.9(c)	343.1(c)	Last
1 655 648	1 654 217	1 752 424	1 730 931	4 506 337	Volume
+0.20%	+1.65%	+0.51%	-0.07%	+1.84%	Change

More quotes

Financials

Sales 2020	61 405 M 67 355 M 67 355 M
Net income 2020	15 030 M 16 487 M 16 487 M
Net cash position 2020	3 301 M 3 621 M 3 621 M
P/E ratio 2020	20,1x
Yield 2020	2,72%

Sales 2021	63 555 M 69 714 M 69 714 M
Net income 2021	16 062 M 17 618 M 17 618 M
Net cash position 2021	11 933 M 13 090 M 13 090 M
P/E ratio 2021	18,7x
Yield 2021	2,82%

Capitalization	293 B 322 B 321 B
EV / Sales 2020	4,72x
EV / Sales 2021	4,42x
Nbr of Employees	97 735
Free-Float	83,6%

More Financials

Company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The...

Sector

Pharmaceuticals

Calendar

09/23 | 03:50am

Presentation

More about the company

Notations Surperformance© of Roche Holding AG

Trading Rating :

Investor Rating :

More Ratings

All news about ROCHE HOLDING AG

09/19	ROCHE : presents new data from multiple Phase III studies of Tecentriq in triple..	PU
09/19	ROCHE : presents new data from multiple Phase III studies of Tecentriq in triple..	AQ
09/19	GENENTECH : Presents New Data From Multiple Phase III Studies of Tecentriq in Tr..	BU
09/19	Roche presents new data from multiple Phase III studies of Tecentriq in tripl..	GL
09/18	ROCHE : rises on word of COVID trial win, new test and European cancer drug nod	RE
09/18	ROCHE : receives positive CHMP opinion for Tecentriq in combination with Avastin..	AQ
09/18	ROCHE : receives positive CHMP opinion for Tecentriq in combination with Avastin..	PU
09/18	ROCHE : receives positive CHMP opinion for Tecentriq in combination with Avastin..	AQ
09/18	Roche receives positive CHMP opinion for Tecentriq in combination with Avasti..	GL
09/18	HALOZYME THERAPEUTICS : Announces Poster Presentation Of Data from Roche's Phase..	AQ
09/18	CORVUS PHARMACEUTICALS : New Data from Ciforadenant Phase 1b/2 Clinical Study Pr..	AQ
09/18	ROCHE : Arthritis Drug Meets Key Endpoint in Covid-19 Pneumonia Study	DJ
09/18	ROCHE HOLDINGS AG : Receives a Buy rating from UBS	MD
09/18	ROCHE : phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood ..	AQ
09/18	ROCHE : Launches Quantitative Test for Coronavirus Antibodies	DJ

More news

News in other languages on ROCHE HOLDING AG

09:12a	Roche présente diverses données sur Tecentriq lors du congrès ESMO
08:49a	Roche präsentiert an ESMO verschiedene Daten zu Tecentriq
09/18	ROCHE : avis positif du CHMP sur Tecentriq
09/18	ROCHE : avis favorable du CMPH pour Tecentriq/Avastin (cancer du foie)
09/18	Roche erhält positive Empfehlung der EU für Tecentriq/Avastin gegen Leberkreb..

More news

Analyst Recommendations on ROCHE HOLDING AG

09/18	ROCHE HOLDINGS AG : Receives a Buy rating from UBS	MD
09/15	ROCHE HOLDINGS AG : Goldman Sachs keeps its Buy rating	MD
09/15	ROCHE HOLDINGS AG : Buy rating from JP Morgan	MD

More recommendations

Stock Trading Strategies

	ROCHE HOLDING AG - 07/28
Back on an important level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Chart ROCHE HOLDING AG

Duration : Period :

Roche Holding AG Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends ROCHE HOLDING AG

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	24
Average target price	379,32 CHF
Last Close Price	343,10 CHF
Spread / Highest target	21,5%
Spread / Average Target	10,6%
Spread / Lowest Target	-5,28%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Severin Schwan	Chief Executive Officer & Executive Director
Christoph Franz	Chairman
Alan Hippe	Chief Financial & Information Technology Officer
Paul Bulcke	Non-Executive Director
André S. Hoffmann	Vice Chairman

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ROCHE HOLDING AG	9.27%	322 209



JOHNSON & JOHNSON	2.27%	392 765
MERCK & CO., INC.	-5.65%	217 034
PFIZER, INC.	-6.02%	203 549
NOVARTIS AG	-9.76%	200 978
NOVO NORDISK A/S	12.50%	161 415

More Results